Loading stock data…
Insulet Corporation (PODD)
$157.74-0.51 (-0.32%)
Market ClosedLast close Jun 29
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $157.74 with a market capitalization of $10.9B. Wall Street consensus targets $240.25 (24 analysts), implying a +52.3% move over the next 12 months. The stock is currently near its 52-week low of $138.79, remaining 37.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +52.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $761.70M↓ | $783.80M↑ | $706.30M↑ | $649.10M↑ | $569.00M |
| Gross Profit | $529.10M↓ | $568.60M↑ | $510.10M↑ | $452.20M↑ | $409.00M |
| Operating Income | $122.20M↓ | $146.30M↑ | $117.70M↓ | $121.10M↑ | $88.70M |
| Net Income | $91.10M↓ | $101.60M↑ | $87.60M↑ | $22.50M↓ | $35.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.86
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.25%
Volume
Today's trading volume
1.50M
Recent News
Do Options Traders Know Something About Insulet Stock We Don't?
Investors need to pay close attention to PODD stock based on the movements in the options market lately.
Insulet (PODD) Just Overtook the 50-Day Moving Average
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
If You Invested $1000 in Insulet 10 Years Ago, This Is How Much You'd Have Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Avoid
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
1 Mid-Cap Stock Worth Your Attention and 2 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.